Abstract
A previous study has shown that there are high levels of an abnormally-fucosylated form of haptoglobin (FHp) in the blood of cancer patients (Thompson & Turner, 1987b). In this study, we investigated the expression of this substance in serial blood specimens from women with ovarian or breast cancer who were undergoing cytotoxic chemotherapy. The level of FHp was related to patient response to therapy status, this latter index being an indirect determination of tumour burden. FHp levels did not correlate with gross liver metastasis (as shown by CT scans or the blood levels of liver enzymes). This conclusion was further supported by results from patients with hepatocellular cancer. FHp was elevated in most of these patients, but the pattern of change did not correlate with variations in the level of the hepatoma marker, alpha-foetoprotein. It seems likely that FHp is produced by the liver. Primary and secondary tumours could release substances, such as cytokines, which interfere with fucose metabolism in the liver.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thompson, S., Cantwell, B., Cornell, C. et al. Abnormally-fucosylated haptoglobin: a cancer marker for tumour burden but not gross liver metastasis. Br J Cancer 64, 386–390 (1991). https://doi.org/10.1038/bjc.1991.314
Issue Date:
DOI: https://doi.org/10.1038/bjc.1991.314
This article is cited by
-
Development of candidate biomarkers for pancreatic ductal adenocarcinoma using multiple reaction monitoring
Biotechnology and Bioprocess Engineering (2013)
-
Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays
Nature Methods (2007)
-
Glycosylation of alpha-1-proteinase inhibitor and haptoglobin in ovarian cancer: evidence for two different mechanisms
Glycoconjugate Journal (1995)
-
Changes in the fucose content of haptoglobin in breast and ovarian cancer: Association with disease progression
Glycosylation & Disease (1994)